1268605-96-4
Chemical Structure
(±)-Lisofylline-d3
Synonym(s): (±)-Lisophylline-d3
- CAS No.: 1268605-96-4
- Formula:C13H17D3N4O3
- Molecular Weight:283.34
IUPAC Name: (E)-4-hydroxy-3-methylbut-2-en-1-yl trihydrogen diphosphate, triammonia salt
InChIKey: NSMXQKNUPPXBRG-BMSJAHLVSA-N
SMILES: O=C(N1CCCCC(O)C)N(C)C2=C(N(C([2H])([2H])[2H])C=N2)C1=O
Biological Activity: (±)-Lisofylline-d3 is the deuterium labeled (±)-Lisofylline[1]. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(±)-Lisofylline-d3 | (±)-Lisofylline-d3 is the deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Lisofylline (Standard) | ≥98% | (±)-Lisofylline (Standard) is the analytical standard of (±)-Lisofylline. This product is intended for research and analytical applications. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Lisofylline-d6 | (±)-Lisofylline-d6 is the deuterium labeled (±)-Lisofylline. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Lisofylline-d4 | (±)-Lisofylline-d4 ((±)-Lisophylline-d4) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Lisofylline | 98.57% | (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
